Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [<SUP>111</SUP>In]In-XYIMSR-01 for phase I regulatory approval

Ravindra A. De Silva,Michael A. Gorin,Ronnie C. Mease,Il Minn,Ala Lisok,Donika Plyku,Sridhar Nimmagadda,Mohamad E. Allaf,Xing Yang,George Sgouros,Steven P. Rowe,Martin G. Pomper

DOI: https://doi.org/10.1002/jlcr.3906

2021-01-01

Abstract:[In-111]In-XYIMSR-01 is a promising single-photon emission computed tomography (SPECT) imaging agent for identification of tumors that overexpress carbonic anhydrase IX. To translate [In-111]In-XYIMSR-01 to phase I trials, we performed animal toxicity and dosimetry studies, determined the maximum dose for human use, and completed the chemistry, manufacturing, and controls component of a standard regulatory application. The production process, quality control testing, stability studies, and specifications for sterile drug product release were based on United States Pharmacopeia chapters and , FDA 21 CFR Part 212. Toxicity was evaluated by using nonradioactive [In-113/115]In-XYIMSR-01 according to 21 CFR Part 58 guidelines. Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA/EXM) was used to calculate the maximum single dose for human studies. Three process validation runs at starting radioactivities of similar to 800 MBq were completed with a minimum concentration of 407 MBq/ml and radiochemical purity of >99% at the end of synthesis. A single intravenous dose of 55 mu g/ml of [In-113/115]In-XYIMSR-01 was well tolerated in male and female Sprague-Dawley rats. The calculated maximum single dose for human injection from dosimetry studies was 390.35 MBq of [In-111]In-XYIMSR-01. We have completed toxicity and dosimetry studies as well as validated a manufacturing process to test [In-111]In-XYIMSR-01 in a phase I clinical trial.